Life Sciences Research Partners VZW
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Apr 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof (US 11,654,201) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Markers for determining tumor hypoxia (US 11,814,688) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jul 19, 2027The maintenance fee for HDAC inhibitors to treat charcot-marie-tooth disease (US 9,238,028) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the DNA base excision repair pathway (US 10,633,707) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,149,914 | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,654,201 | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,409,236 | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,617,548 | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,238,028 | HDAC inhibitors to treat charcot-marie-tooth disease In force · From the USPTO record | In force | From the USPTO record | |
| US 10,633,707 | Markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the DNA base excision repair pathway In force · From the USPTO record | In force | From the USPTO record | |
| US 10,294,529 | Microsatellite Instability Markers in Detection of Cancer In force · High confidence | In force | High confidence | |
| US 11,814,688 | Markers for determining tumor hypoxia In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 8: 11 patents in force now held by others · 33 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 abandoned · 19 no status recorded